The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Open accessAbstract
Context Androgen deprivation therapy (ADT) for prostate cancer (PCa) represents one of the most effective systemic palliative treatments known for solid tumors. Although clinical trials have assessed the role of ADT in patients with metastatic and advanced locoregional disease, the risk–benefit ratio, especially in earlier stages, remains poorly defined. Given the mounting evidence for potentially life-threatening adverse effects with short- and long-term ADT, it is important to redefine the role of ADT for this disease. Objective Review the published experience with currently available ADT approaches in various contemporary clinical settings of PCa and reported serious treatment-related adverse events. This review addresses the level of evidence associated with the use of ADT in PCa, focusing upon survival outcome measures. Furthermore, this paper discusses evolving approaches targeting androgen receptor signaling pathways and emerging evidence from clinical trials with newer compounds. Evidence acquisition A comprehensive review of the literature was performed, focusing on data from the last 10 yr (January 2000 to July 2011) and using the terms androgen deprivation, hormone treatment, prostate cancer and adverse effects. Abstracts from trials reported at international conferences held in 2010 and 2011 were also evaluated. Evidence synthesis Data from randomized controlled trials and population-based studies were analyzed in different clinical paradigms. Specifically, the role of ADT was evaluated in patients with nonmetastatic disease as the primary and sole treatment, in combination with radiation therapy (RT) or after surgery, and in patients with metastatic disease. The data suggest that in men with nonmetastatic disease, the use of primary ADT as monotherapy has not shown a benefit and is not recommended, while ADT combined with conventional-dose RT (<72 Gy) for patients with high-risk disease may delay progression and prolong survival. The postoperative use of ADT remains poorly evaluated in prospective studies. Likewise, there are no trials evaluating the role of ADT in patients with biochemical relapses after surgery or RT. In patients with metastatic disease, there is a clear benefit in terms of quality of life, reduction of disease-associated morbidity, and possibly survival. Treatment with bilateral orchiectomy, luteinizing hormone–releasing hormone agonist therapy, with and without antiandrogens has been associated with various serious adverse events, including cardiovascular disease, diabetes, and skeletal complications that may also affect mortality. Conclusions Although ADT is an effective treatment of PCa, consistent long-term benefits in terms of quality and quantity of life are predominantly evident in patients with advanced/metastatic disease or when ADT is used in combination with RT (<72 Gy) in patients with high-risk tumors. Implementation of ADT should be evidence based, with special consideration to adverse events and the risk–benefit ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“ADT in metastatic disease Start at diagnosis Yes: surgical or chemical castration with continous LHRH-A – Disease flare prevention with AA Yes in all patients, 2–7 d before LHRH-A start 1b [57,63] Abiraterone acetate Yes in docetaxel-treated patients with CRPC 1b [81]”
Self-citationDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · cited 1×
“Compared with the first generation of nonsteroidal AR binders (flutamide, bicalutamide, and nilutamide), MDV3100 and RD162 are orally available drugs that bind the AR with a higher affinity, prevent AR nuclear translocation, and have no agonist activity [83].”
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686 · cited 1×
“The OS difference among the two groups was 20% at both 5 and 10 yr [18,31].”
Self-citationA Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464 · cited 3×
“This problem may be ameliorated by an oral nonsteroidal antiandrogen administered at least 2–7 d before starting the LHRH agonist [57,63].”
Self-citationDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Self-citationThompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M., Oddens, J., Poortmans, P. M. P., Gez, E., Kil, P., Akdas, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970
Bolla, M., Van Tienhoven, G., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Billiet, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70223-0 · Cited by 946
Self-citationPilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 913
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Widmark, A., Klepp, O., Solberg, A., Damber, J.-E., Angelsen, A., Fransson, P., Lund, J.-Å., Tasdemir, I., Hoyer, M., Wiklund, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61815-2 · Cited by 876
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Self-citationMaximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A., Tomaszewski, J. E., Renshaw, A. A., Kaplan, I., Beard, C. J., et al. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61700-2 · Cited by 713
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696
Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial
D’Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 690
Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., Venkatesan, V., Lawton, C. A., Rosenthal, S. A., Sandler, H. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9021 · Cited by 688
Klotz, L. H., BOCCON-GIBOD, L., Shore, N. D., Andreou, C., Persson, B., Cantor, P., Jensen, J.-K., Olesen, T. K., & Schröder, F. H. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08183.x · Cited by 666
Self-citation(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Roach, M., Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Adib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542
Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M.-H., & Carroll, P. R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm168 · Cited by 520
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501 · cited 2×
“The combined analysis of three small RCTs of men with clinically localized PCa found that 6 mo of ADT was associated with earlier onset of fatal myocardial infarction in men aged 65 yr [89].”
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Lawton, C. A., DeSilvio, M., Roach, M., Uhl, V., Kirsch, R., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.003 · Cited by 480
Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial
Beckendorf, V., Guerif, S., Le Prisé, E., Cosset, J.-M., Bougnoux, A., Chauvet, B., Salem, N., Chapet, O., Bourdain, S., Bachaud, J.-M., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.049 · Cited by 452
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 411
Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M.-E., Bubley, G. J., Kheoh, T., Haqq, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9259 · Cited by 410
Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6819 · Cited by 394 · cited 1×
“In phase 2 multicenter trials, abiraterone acetate, at a daily oral dose of 1000 mg, has shown promising clinical activity in patients with metastatic CRPC both before and after treatment with docetaxel [79,80].”
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70348-x · Cited by 375
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 366
IVERSEN, P., TYRRELL, C. J., KAISARY, A. V., ANDERSON, J. B., VAN POPPEL, H., TAMMELA, T. L. J., CHAMBERLAIN, M., CARROLL, K., & MELEZINEK, I. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67032-2 · Cited by 354
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., Ricchiuti, V., Conrad, W., & Resnick, M. I. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64561-2 · Cited by 347
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00388-5 · Cited by 339
Self-citationImpact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Studer, U. E., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T., Hauri, D., Loidl, W., Isorna, S., Sundaram, S. K., Debois, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7423 · Cited by 327
Self-citationSurvival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Lu-Yao, G. L. (2008) · JAMA · doi:10.1001/jama.300.2.173 · Cited by 315
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
Tyrrell, C. J., Kaisary, A. V., Iversen, P., Anderson, J. B., Baert, L., Tammela, T., Chamberlain, M., Webster, A., & Blackledge, G. (1998) · European Urology · doi:10.1159/000019634 · Cited by 306
Oefelein, M. G., Feng, A., Scolieri, M. J., Ricchiutti, D., & Resnick, M. I. (2000) · Urology · doi:10.1016/s0090-4295(00)00793-7 · Cited by 279
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group (2006) · BJU International · doi:10.1111/j.1464-410x.2005.06051.x · Cited by 277
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3752 · Cited by 261
Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3750 · Cited by 251
Moul, J. W., Wu, H., Sun, L., McLeod, D. G., Amling, C., Donahue, T., Kusuda, L., Sexton, W., O’Reilly, K., Hernandez, J., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.03.138 · Cited by 247
Calais da Silva, F. E. C., Bono, A. V., Whelan, P., Brausi, M., Marques Queimadelos, A., Martin, J. A. P., Kirkali, Z., Calais da Silva, F. M. V., & Robertson, C. (2009) · European Urology · doi:10.1016/j.eururo.2009.02.016 · Cited by 243
MOUL, J. W., WU, H., SUN, L., McLEOD, D. G., AMLING, C., DONAHUE, T., KUSUDA, L., SEXTON, W., O’REILLY, K., HERNANDEZ, J., et al. (2004) · Journal of Urology · doi:10.1097/01.ju.0000113794.34810.d0 · Cited by 224
Van Hemelrijck, M., Garmo, H., Holmberg, L., Ingelsson, E., Bratt, O., Bill-Axelson, A., Lambe, M., Stattin, P., & Adolfsson, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.1567 · Cited by 206
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.021 · Cited by 200
五味, 光., 小塚, 拓., & 山下, 孝. (2005) · Mebio oncology · Cited by 192
Smith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188
McLeod, D., Zinner, N., Tomera, K., Gleason, D., Fotheringham, N., Campion, M., & Garnick, M. B. (2001) · Urology · doi:10.1016/s0090-4295(01)01342-5 · Cited by 165
D'Amico, A. V. (2000) · JAMA · doi:10.1001/jama.284.10.1280 · Cited by 158
Studer, U. E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T. M., Knönagel, H., Loidl, W. C., Isorna, S., Sundaram, S. K., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.12.032 · Cited by 151
Self-citationDijkman, G. A., Janknegt, R. A., de Reijke, T. M., & Debruyne, F. M. J. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00051 · Cited by 145
Is the flare phenomenon clinically significant?
Bubley, G. J. (2001) · Urology · doi:10.1016/s0090-4295(01)01235-3 · Cited by 141
Spry, N. A., Kristjanson, L. J., Hooton, B., Hayden, L. J., Neerhut, G., Gurney, H., Corica, T., Korbel, E. I., Weinstein, S. L., & McCaul, K. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.029 · Cited by 122
Labrie, F., Dupont, A., Bélanger, A., & Lachance, R. (1987) · The Journal of Urology · doi:10.1016/s0022-5347(17)43380-5 · Cited by 122
Schröder, F. H., Kurth, K., Fosså, S. D., Hoekstra, W., Karthaus, P., de Prijck, L., & Collette, L. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.008 · Cited by 121
Self-citationCrook, J. M., Ludgate, C. M., Malone, S. C., Lim, J. T. W., Perry, G., Eapen, L., Bowen, J., Robertson, S., & Lockwood, G. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.02.022 · Cited by 112
Bria, E., Cuppone, F., Giannarelli, D., Milella, M., Ruggeri, E. M., Sperduti, I., Pinnarò, P., Terzoli, E., Cognetti, F., & Carlini, P. (2009) · Cancer · doi:10.1002/cncr.24392 · Cited by 91
Granfors, T., Modig, H. G., Damber, J., & Tomić, R. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.03.092 · Cited by 90
Eisenberger, M., Crawford, E. D., Wolf, M. C., Blumenstein, B. A., McLeod, D. G., Benson, R., Dorr, F. A., Benson, M., & Spaulding, J. T. (1994) · PubMed · Cited by 90
Self-citationLage, M. J., Barber, B., & Markus, R. A. (2007) · Urology · doi:10.1016/j.urology.2007.08.012 · Cited by 89
Siddiqui, S. A., Boorjian, S. A., Inman, B. A., Bagniewski, S. M., Bergstralh, E. J., & Blute, M. L. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.01.022 · Cited by 88
Dreicer, R., Agus, D. B., MacVicar, G. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3084 · Cited by 88
Fracture risk in Danish men with prostate cancer: a nationwide register study
Abrahamsen, B., Nielsen, M. F., Eskildsen, P. C., Andersen, J. T., Walter, S., & Brixen, K. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07163.x · Cited by 78
Boccardo, F., Pace, M., RUBAGOTTI, A., Guarneri, D., DeCensi, A., Oneto, F., Martorana, G. E., Giuliani, L., Selvaggi, F. P., Battaglia, M., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80293-x · Cited by 77
See, W. A., Tyrrell, C., & on behalf of the CASODEX™ Early Prostate Cancer Trialists’ Group (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0132-6 · Cited by 75
Early Androgen Deprivation for Prostate Cancer?
Eisenberger, M. A., & Walsh, P. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412409 · Cited by 74
Self-citationEarly Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate
Ryan, C. J., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.5311 · Cited by 59
The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer
Wong, Y., Freedland, S. J., Egleston, B. L., Vapiwala, N., Uzzo, R. G., & Armstrong, K. (2009) · European Urology · doi:10.1016/j.eururo.2009.03.066 · Cited by 58
Intermittent versus continuous androgen suppression for prostatic cancer
de Conti, P., Atallah, Á. N., de Arruda, H. O., Soares, B. G., Dib, R. E., & Wilt, T. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005009.pub2 · Cited by 51
Boccardo, F., Barichello, M., Battaglia, M., CARMIGNANI, G., Comeri, G., Ferraris, V., Lilliu, S., Montefiore, F., Portoghese, F., Cortellini, P., et al. (2002) · European Urology · doi:10.1016/s0302-2838(02)00435-9 · Cited by 50
Shipley, W. U., Hunt, D. L., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Patel, M., Bahary, J.-P., Lawton, C. A., & Sandler, H. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.103 · Cited by 47
McLeod, D. G., See, W. A., Klimberg, I. W., Gleason, D. M., Chodak, G. W., Montie, J. E., Bernstein, G., Morris, C. D., Armstrong, J., & Casodex™ Early Prostate Cancer Trialists’ Group (2006) · The Journal of Urology · doi:10.1016/s0022-5347(06)00495-2 · Cited by 46
Tyrrell, C., Iversen, P., Tammela, T. L. J., Anderson, J., Björk, T., Kaisary, A. V., & Morris, T. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06275.x · Cited by 32
Nguyen, K. H., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., & Pollack, A. S. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00573-x · Cited by 29
Nguyen, P. L., Chen, M. H., Goldhaber, S. Z., et al. (2010) · Cancer · doi:10.1002/cncr.25597 · Cited by 28
Dreicer, R. (2013) · Clinical and Experimental Pharmacology · Cited by 28
Oefelein, M. G. (2003) · The Journal of Urology · doi:10.1016/s0022-5347(05)64079-7 · Cited by 27
Collette, L., Studer, U. E., Schröder, F. H., Denis, L. J., & Sylvester, R. J. (2001) · The Prostate · doi:10.1002/pros.1078 · Cited by 25
Self-citationGilligan, T. D., & Oh, W. K. (2001) · The Prostate Journal · doi:10.1046/j.1525-1411.2001.003001042.x · Cited by 18
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Self-citationTilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Albertsen, P. C., Klotz, L., Tombal, B., Grady, J., Olesen, T. K., & Nilsson, J. (2014) · European Urology · doi:10.1016/j.eururo.2013.10.032 · Cited by 341
Itkonen, H. M., Minner, S., Guldvik, I. J., Sandmann, M. J., Tsourlakis, M. C., Berge, V., Svindland, A., Schlomm, T., & Mills, I. G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0549 · Cited by 292
Yunfeng, G., Weiyang, H., Xueyang, H., Yilong, H., & Xin, G. (2017) · Medicine · doi:10.1097/md.0000000000007368 · Cited by 60
Metadata
- Authors
- Pagliarulo, V., Bracarda, S., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 61
- Issue
- 1
- Pages
- 11-25
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2103531329
- Cited by
- 266
- References
- 95
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.